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Abstract
B10 is a glycosylated derivative of betulinic acid with promising activity against glioma cells. Lysosomal cell death pathways
appear to be essential for its cytotoxicity. We investigated the influence of hypoxia, nutrient deprivation and current
standard therapies on B10 cytotoxicity. The human glioma cell lines LN-308 and LNT-229 were exposed to B10 alone or
together with irradiation, temozolomide, nutrient deprivation or hypoxia. Cell growth and viability were evaluated by crystal
violet staining, clonogenicity assays, propidium iodide uptake and LDH release assays. Cell death was examined using an
inhibitor of lysosomal acidification (bafilomycin A1), a cathepsin inhibitor (CA074-Me) and a short-hairpin RNA targeting
cathepsin B. Hypoxia substantially enhanced B10-induced cell death. This effect was sensitive to bafilomycin A1 and thus
dependent on hypoxia-induced lysosomal acidification. Cathepsin B appeared to mediate cell death because either the
inhibitor CA074-Me or cathepsin B gene silencing rescued glioma cells from B10 toxicity under hypoxia. B10 is a novel
antitumor agent with substantially enhanced cytotoxicity under hypoxia conferred by increased lysosomal cell death
pathway activation. Given the importance of hypoxia for therapy resistance, malignant progression, and as a result of
antiangiogenic therapies, B10 might be a promising strategy for hypoxic tumors like malignant glioma.
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Introduction
Malignant gliomas are among the most aggressive cancer types,
often show resistance to therapy and have a dismal prognosis.
Current treatment includes tumor resection, radiotherapy and
chemotherapy with the DNA methylating drug temozolomide [1].
Furthermore, DNA alkylating nitrosoureas like lomustin and the
VEGF-A antibody bevacizumab are commonly used [2,3].
Beyond these compounds neither targeted therapy nor any other
cytotoxic agent has shown compelling clinical activity yet.
Therefore, agents with new mechanisms of action are urgently
needed.
A wealth of natural compounds has shown substantial
anticancer activity. Betulinic acid, a pentacyclic triterpenoid
discovered in the bark of the white birch tree, has received
particular attention because it shows multiple biological activities,
including anticancer properties [4,5]. Due to its low solubility in
aqueous solvents and the poor understanding of its mode of action,
the therapeutic applicability is, however, limited. Therefore,
several semi-synthetic derivatives of betulinic acid have been
generated [6]. B10 is a new glycosylated derivative of betulinic
acid with enhanced cytotoxic activity that has recently been shown
to trigger cell death via the lysosomal pathway [7]. As the study by
Gonzalez and colleagues is the only work on B10 and limited to in
vitro experiments, in vivo or even clinical experience on B10 is
lacking.
Gonzalez and colleagues found that the morphology of B10-
induced cell death is rarely typical for apoptosis. In comparison to
TRAIL-induced cell death, B10 causes only a slight degree of
DNA fragmentation. In addition, bcl-2 overexpression fails to
prevent B10-induced cell death. Knockdown of caspase-3 results
in a significant but incomplete decrease of B10 cytotoxicity. A
transient increase of the acidic (lysosomal) compartment within
9 h of B10 treatment is followed by a decrease from 15 h onwards.
Moreover, B10 treatment results in a shift of the lysosomal
enzymes cathepsin Z and cathepsin B (CTSB) from lysosomes to
cytoplasm and nucleus, further corroborating the hypothesis that
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B10 induces a permeabilization of lysosomes. These results are
confirmed by the finding of a delay in B10-induced cell death
under co-treatment with the cathepsin inhibitor CA074-Me,
whereas other inhibitors of lysosomal enzymes do not impair
B10 activity. Thus, lysosomal enzymes and their release contribute
to B10-triggered cell death.
The major physiological inductor of autophagy is nutrient
starvation [8]. Furthermore, it has been shown in vitro that
hypoxia induces autophagy in cancer cells including two glioma
cell lines [9,10]. Hypoxia induces double-membraned autophago-
somes as seen in electron microscopy, leading to GFP-LC3
punctate staining with LC3-II accumulation and an increased
production of acidic vesicular organelles. Shortage of nutrients and
oxygen is a central feature of malignant gliomas.
In this study, we investigated whether the sensitivity of glioma
cells to B10 is altered under hypoxic conditions or nutrient
deprivation. This question is of particular interest because the
efficacy of current cytostatic drugs is often impaired under these
conditions [11].
Materials and Methods
Reagents, cell lines and culture conditions
B10 was synthesized by BioService Halle (Halle, Germany).
CA074-Me was purchased from Enzo Life Sciences (Lo¨rrach,
Germany). All reagents not specified were purchased from Sigma
(Taufkirchen, Germany). LNT-229 cells have been described [12];
LNT-229 and LN-308 cells were a kind gift of Dr. N de Tribolet
(Lausanne, Switzerland) [13]. Cell lines were maintained in
Dulbecco’s modified eagle medium (DMEM) containing 10%
fetal calf serum (FCS) (Biochrom KG, Berlin, Germany), 100 IU/
ml penicillin and 100 mg/ml streptomycin (Life Technologies,
Karlsruhe, Germany) [12].
Primary cell culture
R28 primary glioblastoma cells (passage 10) were a kind gift of
Dr. Christoph Beier and have been described [14]. MNOF132
(passage 6) were derived from a glioblastoma and MNOF168 cells
(passage 14) were derived from a gliosarcoma both resected at the
Goethe University Hospital in Frankfurt. MNOF132 and
MNOF168 cells were a kind gift of Dr. Stefan Momma. Primary
cell cultures were maintained in DMEM-F12 medium containing
20 ng/ml of each human recombinant epidermal growth factor
(EGF) and human recombinant basic fibroblast growth factor
(bFGF) (both from ReliaTech, Wolfenbu¨ttel, Germany) as well as
20% BIT Admixture 100 supplement (Pelo Biotech, Planegg/
Martinsried, Germany). These culture conditions enable tumor
cells to maintain most of the characteristics of the original tumor
including differentiation, expression pattern, and genetic mutation
profile [14,15]. New/additional EGF and bFGF (each 20 ng/ml)
was added to the cell culture twice per week. For experiments
flasks/wells were coated with 5 mg/ml laminin (Sigma, Deisenho-
fen, Germany) for 3 h, primary cells were allowed to attach for two
days before the beginning of any experiment. Hypoxia experi-
ments were conducted in serum-free DMEM containing 2 mM
glucose in accordance to the experimental setup with established
glioma cell lines.
Induction of hypoxia
Hypoxia was induced as previously described [12,16]. Briefly,
0.1% O2 was induced by incubation in Gas-pak pouches for
anaerobic culture (Becton-Dickinson, Heidelberg, Germany) [17].
Cell density measurement after 48 h cannot accurately be
performed under 0.1% O2 due to cellular detachment. Therefore,
moderate hypoxia (1% O2) used for cell density measurements was
induced in a Labotect incubator (Goettingen, Germany). Cells
were seeded and allowed to attach in DMEM containing 10%
FCS for 24 h under normoxia. Subsequently, the medium was
removed and the cells were incubated in serum-free DMEM
adjusted to 2 mM glucose under normoxia, 1% O2 or 0.1% O2 for
the indicated intervals. Equal cell densities were ensured by crystal
violet (CV) staining when comparing LN-308 sub cell lines (Scrsh
and CTSBsh) [12].
Western Blot analysis
After the incubation period, cells were washed with ice-cold PBS
and harvested into ice-cold PBS containing protease inhibitors.
Lysates were prepared as described using lysis buffer P and
subjected to SDS-PAGE analysis [17]. Membranes were probed
with antibodies to HIF-1a (BD Transduction Laboratories #
610958) or actin (Santa Cruz Biotechnology, # sc-1616). The
secondary anti-rabbit and anti-goat antibodies were purchased from
Santa Cruz Biotechnology. Chemiluminescence solution was used
for detection and was composed of 1 ml solution A (200 ml 0.1 M
Tris-HCl pH 8.6, 50 mg Luminol), 100 ml solution B (11 mg p-
hydroxycurmarinacid, 10 ml DMSO) and 0.3 ml H2O2 (30%).
Irradiation
Irradiation was administered at room temperature with single
doses of X-rays ranging from 2 to 6 Gy using a linear accelerator
(SL 75/5, Elekta, Crawley, UK) with 6 MeV photons/100 cm
focus–surface distance with a dose rate of 4.0 Gy/min [18].
Control cells were also brought to the irradiation chamber but
were not placed under the X-ray beam.
Cell density and cell viability assays
Cell density was assessed by CV staining as previously described
[19,20]. Cell viability measurement using propidium iodide (PI)
uptake and flow cytometry has been described [12]. Analysis was
performed by flow cytometry employing a BD Canto II flow
cytometer and Summit 4.2. software. Cell viability analysis by lactate
dehydrogenase (LDH) release assay was performed with the
Cytotoxicity Detection Kit (LDH) (Roche, Mannheim, Germany)
[11,12]. Trypan blue solution (0.4%) was purchased from Sigma. For
cell viability analysis, the culture medium was diluted by an equal
volume of trypan blue solution and the cells were incubated for
10 min. After the incubation period, the cells were pelleted by
centrifugation (300 g) and the supernatant was carefully replaced by
PBS. Finally, the cells were photographed with a Keyence BZ 8000
fluorescence microscope (Lightfield Channel) using BZ observation
application software and a 206magnification. Viable and dead cells
were determined by manual counting. For clonogenicity analysis,
500 cells were seeded per well of a 6 well plate. After incubation
overnight, the cells were exposed to B10 or temozolomide or
irradiation or combinations thereof. 24 h after treatment the medium
was replaced by fresh DMEM containing 10% FCS. Experiments
were stopped by CV staining when two clones came close to being
indistinguishable. The ATP assay (CLS II kit) was purchased from
Roche. For ATP measurement, immediately after normoxic or
hypoxic incubation, the plates were placed on ice, the cells pelleted by
centrifugation and lysed in ATP releasing reagent (Sigma). The ATP
concentration was determined by a luciferase assay using MikroWin
2000 software and a Mithras luminometer [17].
Lysotracker staining, microscopy and quantification
Lysotracker red was purchased from Invitrogen (Karlsruhe,
Germany). Live cell staining was performed according to the
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manufacturer’s protocol using 50 nM Lysotracker. In brief, for
staining we added Lysotracker to the culture medium to a final
concentration of 50 nM and cells were incubated at 37uC in the
dark for 10 minutes. Afterwards cells were analysed with a
Keyence BZ 8000 fluorescence microscope (Texas Red Channel)
using BZ observation application software. Lightfield images of
primary glioma cells were acquired using the corresponding
channel of the microscope. Quantification of the Lysotracker
signal of the acquired photographs (Texas Red Channel) was
accomplished by measuring the mean pixel intensity values for six
independent visual fields of equal cell density using ImageJ v 1.48r
software (http://imagej.nih.gov/ij/).
Cathepsin B activity assay
Cathepsin B activity was measured using the fluorogenic
cathepsin B activity assay Kit (Calbiochem CBA001, Darmstadt,
Germany). To ensure comparability between sub cell lines,
samples were normalized for protein concentration. Protein
concentration was measured using a Bradford protocol.
Plasmids and lentivirus production
The pLKO.1 plasmid targeting cathepsin B (CTSB) was ordered
from Sigma (TRCN0000003658), the pLKO.1 plasmid with a non-
targeting shRNA sequence was from Addgene (# 1864). Lentiviral
production was perfomed according to the Addgene protocol in
HEK293 cells using the packaging plasmid pCMV-dR8.2 dvpr
(Addgene #8455) and envelope plasmid pCMV-VSVG (Addgene
#8454). Lentiviral infection was done in the presence of polybrene
(Millipore, Darmstadt, Germany). For selection 2 mg/ml puromycin
(Sigma) was added to the culture medium.
RNA extraction and quantitative reverse transcription-
PCR (qRT-PCR) analysis
qRT-PCR has been described [16]. Briefly, for RNA purifica-
tion TRIzol and the RNAeasy Kit (Invitrogen, Karlsruhe,
Germany) were used. cDNA was synthesized with the Vilo cDNA
synthesis kit (Invitrogen) (10 min at 25uC followed by 2 h at 42uC).
Subsequently, the reaction was stopped at 85uC for 10 min. qRT-
PCR was performed in the IQ5 real-time PCR detection system
(Biorad, Munich, Germany) using Absolute Blue Q-PCR Mas-
termix with SybrGreen+Fluorescein (Thermo Fisher Scientific,
Hamburg, Germany) and the following primer pairs: CTSB: Fwd:
59-ACAGCCCGACCTACAAACAG-39, Rev: 59-CCAGTAG-
GGTGTGCCATTCT-39 (designed using Primer3 [21]); 18S:
Fwd: 59-CGGCTACCACATCCAAGGAA-39, Rev: 59-GC-
TGGAATTACCGCGGCT-39; Succinate-dehydrogenase com-
plex subunit A (SDHA): Fwd: 59-TGGGAACAAGAGGG-
CATCTG-39, Rev: 59-CCACCACTGCATCAAATTCATG-39,
carboanhydrase IX (CAIX): Fwd: 59-AAGAAGAGGGCT-
CCCTGAAG-39, Rev: 59-TAGCGCCAATGACTCTGGTC-39;
vascular endothelial growth factor (VEGF): Fwd: 59-
AGCCTTGCCTTGCTGCTCTA-39, Rev:: 59-GTGCT-
GGCCTTGGTGAGG-39. 18S and SDHA were both used as
housekeeping genes for normalization. Cycle threshold (Ct) values
were normalized for amplification of the 18S ribosomal RNA and
the data were analyzed using the Vandesompele method [22].
Results
B10 shows cytotoxic effects on glioma cells
After 48 h of exposure to B10 the concentrations resulting in a
50% decrease of cell density ranged from 7 to 21 mM (Fig. S1A).
Moreover, B10 treatment resulted in a dramatic increase in PI
uptake (Fig. S1B) and strong LDH-release (Fig. S1C). LN-308 and
LNT-229 cells were selected for further studies. The threshold
concentration of 10 mM B10 was chosen for further experiments
(red rectangle in Fig. S1B, S1C).
Hypoxia enhances B10 cytotoxicity
We exposed glioma cells to B10 either under normoxic or
hypoxic conditions (1% or 0.1% O2) to investigate whether
malignant glioma cells are particularly sensitive for B10 cytotox-
icity under hypoxic conditions. Increased levels of HIF-1a as well
as HIF-1a target gene induction under hypoxic conditions are
shown in figure S2. CV staining showed a dramatic sensitization of
LN-308 and LNT-229 cells to B10 under hypoxia with a decline in
cell density (Fig. 1A). This sensitization also became evident by an
increase in trypan blue staining (Fig. S3A). In addition, we found a
strong and concentration-dependent increase of LDH release from
LN-308 and LNT-229 cells after exposure to B10 under hypoxic
conditions (Fig. 1B, Fig. S3B). These results were further
corroborated by an increase of PI-positive cells in LN-308 and
LNT-229 (Fig. 1C, D) as well as by an accelerated ATP depletion
in hypoxia in the presence of B10 (Fig. S3C).
To further generalize these results, we treated primary brain
cancer cells with B10 under normoxic or hypoxic conditions. The
enhanced toxicity of B10 under hypoxic conditions also occurs in
primary cell lines (Fig. S3D, E).
Glucose deprivation does not alter B10 cytotoxicity
To address whether B10 cytotoxicity is influenced by nutrient
depletion, we changed culture conditions by reducing glucose to
2 mM [11] which more accurately reflects in vivo tumor
conditions. Glucose deprivation did not sensitize LN-308 cells to
B10 toxicity as shown by cell density analysis (Fig. S4A) and PI
uptake (Fig. S4B). Similar results were obtained by LDH release
and for LNT-229 cells (data not shown).
Combining B10 with temozolomide or irradiation shows
additive cytotoxicity
To analyze any potential synergy of B10 and temozolomide,
we investigated effects on clonogenic survival of LN-308 and
LNT-229 cells and found additive inhibition of clonogenicity (Fig.
S5A, B). Similarly, we tested for synergy of B10 and irradiation
and again found additive effects for the reduction of clonogenicity
(Fig. S5C, D). Further, we exposed LN-308 and LNT-229 cells to
B10, temozolomide or their combination. CV and PI staining as
well as LDH-release confirmed additive cytotoxicity (data not
shown).
Inhibition of lysosomal acidification rescues glioma cells
from B10 toxicity under hypoxic conditions
To clarify the role of lysosomal cell death pathways for the
increased cytotoxicity of B10 under hypoxic conditions, we
examined whether glioma cells are rescued by inhibition of
lysosomal acidification. BafA1 is an inhibitor of the vacuolar type
H+-ATPase (V-ATPase) and thereby prevents acidification of
lysosomes, resulting in reduced activity of lysosomal enzymes and
blockade of the fusion of lysosomes and autophagosomes [23].
BafA1 almost completely rescued glioma cells from B10 cytotox-
icity under hypoxic conditions. Cotreatment with B10 and BafA1
resulted in a cell density close to values of vehicle treatment
(Fig. 2A). This was further corroborated by a reduction of LDH
release (Fig. 2B) in LN-308 and LNT-229.
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Inhibition of cathepsins protects glioma cells against B10
cytotoxicity under hypoxic conditions
It has been shown that B10 ultimately leads to a permeabiliza-
tion of lysosomes and release of cathepsins to the cytosol [7].
Therefore, we determined the effect of CA074-Me, an inhibitor of
cathepsin B, L and S, on the cytotoxicity of B10 under hypoxic
conditions. CA074-Me attenuated the effects of B10 on cell density
and LDH-release under hypoxia in LN-308 and LNT-299 cells
(Fig. 2C, D).
Hypoxia increases lysosomal acidification and cathepsin
B activity
B10 cytotoxicity under hypoxic conditions seems to depend on
lysosomal acidification. Therefore, we looked for changes of the
Figure 1. B10-induced cell death is substantially enhanced by hypoxia. A, LN-308 or LNT-229 cells were exposed to normoxia or 1% O2 with
or without 10 mM B10 for 48 h. Cell density was measured by CV (LN-308 n= 3, LNT-229 n= 6, SD, *p,0.05). B, LN-308 or LNT-229 cells were treated
with increasing concentrations of B10 under normoxia or 0.1% O2 for 20 h (LN-308) or 27 h (LNT-229). Cell death was quantified by LDH release (n = 4,
SD, *p,0.05). C, LN-308 or LNT-229 cells were exposed to vehicle or 10 mM B10 under normoxia or 0.1% O2 for 23 h (LN-308) or 24 h (LNT-229). Cell
death was measured by PI uptake. Representative flow cytometry profiles are shown. D, Quantification of cell death by PI uptake. LN-308 or LNT-229
cells were exposed to vehicle or 10 mM B10 under normoxia or 0.1% O2 for 23 h (LN-308) or 24 h (LNT-229) (LN-308 n= 3, SD; LNT-229 n= 4, SD, *p,
0.05).
doi:10.1371/journal.pone.0094921.g001
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Figure 2. Blocking lysosomal acidification or inhibiting cathepsin B rescues glioma cells from B10 cytotoxicity under hypoxia. To
block lysosomal acidification we used bafilomycin A1 (BafA1). A, LN-308 or LNT-229 cells were co-treated with 10 nM BafA1 and 10 mM B10 under
hypoxic conditions (1% O2) for 48 h. Cell density was assessed by CV (n = 4, SD, *p,0.05). B, cell death was quantified by LDH-release after treating
LN-308 or LNT-229 cells with BafA1 and B10 under hypoxic conditions (0.1% O2) for 19 h (LN-308) or 27 h (LNT-229) (n = 4, SD, * = p,0.05). To inhibit
cathepsin B we used the cathepsin inhibitor CA074-Me. C, LN-308 or LNT-229 cells were co-treated with 10 mM CA074-Me and 10 mM B10 under
hypoxic conditions (1% O2) for 48 h. Cell density was assessed by CV (n = 4, SD, *p,0.05). D, cell death was quantified by LDH release after treating
LN-308 or LNT-229 cells with CA074-Me and B10 under hypoxic conditions (0.1% O2) for 19 h (LN-308) or 25 h (LNT-229) (n = 4, SD, *p,0.05).
doi:10.1371/journal.pone.0094921.g002
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Figure 3. Hypoxia increases lysosomal acidification and cathepsin B activity. A, LN-308 or LNT-229 cells were grown under normoxia or
hypoxia (0.1% O2) for 10 h and thereafter the lysosomal compartment was stained using Lysotracker red. Representative images are shown. Mean
pixel intensities were measured with ImageJ software (n = 6, SD, *p,0.05). B, cathepsin B activity in LN-308 cells was measured after 8 h of hypoxia.
doi:10.1371/journal.pone.0094921.g003
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lysosomal compartment and cathepsin B activity under hypoxia.
Lysosomal acidification was increased under hypoxia as measured
by Lysotracker staining in LN-308 and LNT-229 cells (Fig. 3A). As
expected, BafA1 almost completely abolished Lysotracker staining
(Fig. 3A). In addition, hypoxia also increased cathepsin B activity
by more than 50% in LN-308 cells (Fig. 3B).
Gene suppression of cathepsin B rescues glioma cells
from B10 cytotoxicity under hypoxia
To further examine the role of cathepsins in B10 cytotoxicity
under hypoxic conditions we generated a stable knockdown of
cathepsin B in LN-308. Efficacy of the knockdown sequence was
tested by quantitative PCR (Fig. 4A). A cathepsin B activity assay
proved the biological consequences of the knockdown (Fig. 4B).
Importantly, LN-308 CTSBsh cells displayed reduced LDH-
release upon B10 exposure, corroborating the central role of
cathepsin B in B10-induced cytotoxicity under hypoxic conditions
(Fig. 4C). The fact that the effects in LN-308 CTSBsh cells do not
equal those of CA074-Me (Fig. 2D) is most likely due to the
incomplete inhibition of cathepsin B activity which was also
reflected in the activity assay (Fig. 4B).
REMBRANDT database analysis
An analysis using the REpository for Molecular BRAinNeopla-
siaDaTa (REMBRANDT; https://caintegrator.nci.nih.gov/
rembrandt/) shows that upregulated cathepsin B gene expression
is associated with a shorter overall survival for the group of all
glioma (Fig. 5A) [24]. This effect seemed to be caused by a high
expression of cathepsin B in glioblastoma tissue. A survival analysis
for cathepsin B gene expression in glioblastoma did not show a
significant difference in overall survival in the REMBRANDT
database on the basis of mRNA expression data (Fig. 5B).
Discussion
Glioblastoma are among the most aggressive tumors and new
therapeutic strategies are desperately needed. We here present
new data on B10, a glycosylated derivative of the natural
compound betulinic acid that was shown to have antiglioma
activity in vitro by impairing lysosomal integrity [7]. We found
that B10 cytotoxicity was augmented under hypoxic conditions.
Furthermore, this effect was strongly dependent on lysosomal
acidification as well as on cathepsin B expression as illustrated in a
proposed model of action (Fig. 6). Despite the missing knowledge
on a defined molecular target, B10 might therefore have a
promising therapeutic potential due to its preference for hypoxic
tumor cells that are usually difficult to treat.
One possible explanation why in vitro data often have limited
validity in vivo is neglect for the actual conditions of the tumor
microenvironment with nutrient deprivation and hypoxia. Both
conditions are typical features of glioblastoma and are supposed to
induce autophagy. No changes in B10 cytotoxicity were observed
under low glucose conditions (Fig. S4). Intriguingly, we found a
substantial increase of B10 cytotoxicity under hypoxia (Fig. 1).
Lysosomal cell death pathways might be relevant for B10
cytotoxicity under hypoxia, since inhibition of lysosomal acidifi-
cation or inhibition of cathepsins was capable to partially but
distinctly rescue glioma cells (Fig. 2). Furthermore, hypoxia
increased the lysosomal compartment and cathepsin B activity
(Fig. 3). The inhibition of lysosomal acidification is an indirect way
to inhibit cathepsins because a low pH is a prerequisite for their
processing and full enzymatic activity. The relevance of our
findings is underscored by the fact that cathepsin B activity is
typically increased under hypoxia, which is a hallmark of
Figure 4. Gene suppression of cathepsin B rescues glioma cells
from hypoxia sensitization to B10. Using a pLKO.1-based lentivirus
LN-308 cathepsin B (CTSB) knockdown cells and control cells (non-
targeting sequence, Scrsh) were generated. CTSB gene suppression was
confirmed by qRT-PCR (A) and CTSB activity (B) (n = 3, SD, *p,0.05). The
effect of the cathepsin inhibitor CA074-Me (10 mM) on cathepsin B
activity in control cells (Scrsh) is shown in B. C, B10-mediated
cytotoxicity under 0.1% O2 in LN-308 control cells and CTSBsh cells
was quantified by LDH-release assay (n = 4, SD, *p,0.05).
doi:10.1371/journal.pone.0094921.g004
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glioblastoma [25,26]. In addition, our analysis of the RE-
MBRANDT database shows that upregulated cathepsin B gene
expression is associated with a shorter overall survival for the
group of all glioma (Fig. 5A). This effect seems to be caused by a
high expression of cathepsin B in glioblastoma tissue. A survival
analysis for cathepsin B gene expression in glioblastoma did not
show a significant difference in overall survival at least in the
REMBRANDT database on the basis of mRNA expression data
(Fig. 5B). In contrast, however, Colin and colleagues showed that
cathepsin B gene expression and cathepsin B protein levels are
predictors for survival in two large independent cohorts [25]. In
addition, they found that cathepsin B was highly expressed in
tumor cells with an emphasis on the hypoxic pseudopalisading
cells surrounding necrotic areas.
Glioblastomas usually show regions of hypoxia and current
treatment standards often lose their activity in these areas due to
reduced perfusion or unfavorable microenvironment. Moreover,
antiangiogenic agents like bevacizumab seem to increase the
extent and degree of hypoxia, thereby worsening this dilemma.
Therefore, B10 seems to be a promising new agent because of its
particular efficacy under hypoxic conditions.
Figure 5. Survival analysis using the REMBRANDT database. A, The survival analysis in the group of all glioma patients reveals an inferior
outcome for patients with a
survival difference was found when restricting this analysis on glioblastoma patients (CTSB upregulated, n = 48; CTSB intermediate, n = 132).
REMBRANDT database accessed June 18th 2013.
doi:10.1371/journal.pone.0094921.g005
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 $ 2-fold upregulation of CTSB gene expression (CTSB-upregulated, n = 58; CTSB intermediate, n = 282; p = 0.004). B, No
Supporting Information
Figure S1 B10 is cytotoxic to human malignant glioma
cells. Glioma cells were exposed to increasing concentrations of
B10 in standard culture conditions (10% FBS, 25 mM glucose,
normoxia). Based on CV staining for cell density we calculated
EC50 values for 10 glioma cell lines (A) (n = 3). Cell death was
quantified by LDH-release in LNT-229 cells (B) (n = 4, SD) and PI
uptake in LN-308 (C) (n = 3, SD).
(TIF)
Figure S2 Hypoxia induces HIF1-a protein levels and
transcriptional targets. A, LN-308 and LNT-229 cells were
exposed to normoxia or hypoxia (0.1% O2) for 8 h in serum-free
DMEM containing 2 mM glucose. Cellular lysates were analyzed
by immunoblot with antibodies for Hif1-a and actin. B, LN-308 or
LNT-229 cells were exposed to normoxia, 1% or 0.1% O2 for 8 h
in serum-free DMEM containing 2 mM glucose. Gene expression
was analyzed by qRT-PCR with primers for CAIX or VEGF
relative to 18S and SDHA. as housekeeping genes for normali-
zation.
(TIF)
Figure S3 B10-induced cell death is substantially en-
hanced by hypoxia in LN-308, LNT-229 and primary
glioma cells. A, LN-308 or LNT-229 cells were treated with
vehicle or 10 mM B10 under normoxia or 1% O2 for 23 h (LN-
308) or 38 h (LNT-229). Cell death was quantified by trypan blue
staining (LN-308 n= 8, LNT-229 n= 6, SD, * = p,0.05).
Representative photographs are included. B, LN-308 or LNT-
229 cells were treated with vehicle or 10 mM B10 under normoxia
or 0.1% O2 for 25 h. Cell death was quantified by LDH release
(n = 8, SD, *p,0.05). C, LN-308 or LNT-229 cells were treated
with vehicle or 10 mM B10 under normoxia or 0.1% O2 for 16 h.
ATP was quantified by a luciferase-based assay (LN-308 n= 5,
LNT-229 n= 7, SD, * = p,0.05). The ratio of ATP concentra-
tions in B10-exposed cells to vehicle-treated cells is depicted. D,
R28 and MNOF132 primary glioma cells were exposed to
normoxia or 1% O2 with or without 10 mM B10 for 48 h. Cell
density was measured by CV staining (n = 5, SD). Representative
light microscopy photographs of R28 cells ultimately before CV
staining are shown (right panel). E, R28 and MNOF168 cells were
treated with 10 mM B10 under normoxia or 0.1% O2. LDH-
release assay shows enhanced toxicity of B10 under hypoxia (n = 4,
SD, *p,0.05).
(TIF)
Figure S4 Glucose deprivation does not increase B10
cytotoxicity. LN-308 cells were treated with 10 mM B10 in full
medium for 3 days with different concentrations of glucose. Cell
density was assessed by CV (A) (n = 3, 6 SD) or by PI uptake (B)
(n = 3, SD).
(TIF)
Figure S5 Cotreatment of glioma cells with B10 with
temozolomide or irradiation has additive anti-clono-
genic effects. A-D, LN-308 (A) and LNT-229 (B) cells were
treated with increasing concentrations of temozolomide (TMZ) or
increasing doses of irradiation (C, D) in the absence or presence of
different concentrations of B10 for 24 h under normoxia.
Thereafter, treatment medium was replaced by fresh DMEM
containing 10% FCS. Experiments were stopped by CV staining
when two clones came close to being indistinguishable (n = 3, SD).
(TIF)
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Figure 6. Proposed mode of action of B10 under hypoxic conditions. Under hypoxic conditions the lysosomal compartment and cathepsin B
activity increase. This sensitizes glioma cells for B10, exploiting lysosomal permeabilization and cathepsin B release to induce lysosomal cell death.
doi:10.1371/journal.pone.0094921.g006
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